These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 34528723)

  • 1. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
    Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
    Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
    Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
    Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
    Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease.
    Suzuki Y; Maekawa S; Yamashita K; Osawa L; Komiyama Y; Nakakuki N; Takada H; Muraoka M; Sato M; Takano S; Fukasawa M; Yamaguchi T; Funayama S; Morisaka H; Onishi H; Enomoto N
    J Gastroenterol Hepatol; 2023 Jun; 38(6):921-929. PubMed ID: 36811251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
    Fruchart JC; Hermans MP; Fruchart-Najib J; Kodama T
    Curr Atheroscler Rep; 2021 Jan; 23(1):3. PubMed ID: 33392801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
    Yamada-Shimizu M; Tamaki N; Kurosaki M; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Ishido S; Nobusawa T; Matsumoto H; Keitoku T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    Intern Med; 2024 May; 63(9):1185-1190. PubMed ID: 37779070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
    Yokote K; Yamashita S; Arai H; Araki E; Suganami H; Ishibashi S; Of The K-Study Group OB
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30736366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
    Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
    Atherosclerosis; 2017 Jun; 261():144-152. PubMed ID: 28410749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
    Flint A; Andersen G; Hockings P; Johansson L; Morsing A; Sundby Palle M; Vogl T; Loomba R; Plum-Mörschel L
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1150-1161. PubMed ID: 34570916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
    Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
    Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
    Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
    Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
    Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.